Erythropoietic therapy: Cost efficiency and reimbursement

Abstract

Initiating a blood management program requires planning and support from those who are concerned about blood usage reduction and outcomes improvement. Launching a vigorous and ongoing educational program to raise awareness about the risks and hazards associated with blood transfusion is an important step in helping to reshape the medical staffs' attitudes about transfusion and the most cost-effective way to achieve clinical goals.

Big data modeling to predict platelet usage and minimize wastage in a tertiary care system

“…We aim to build and validate a reliable statistical model for blood banking that would have a highly significant impact in improving quality, safety, access to care, and cost of care. Measures to increase efficiency and cost-effectiveness in health care are becoming increasingly important ( 7 , 8 ), and an accurate predictive algorithm for blood product usage could greatly contribute to value-based care in transfusion medicine.…”

A Comparative Review of Erythropoiesis Stimulating Agents

“…In a prospective analysis of nearly 300 men undergoing radical retropubic prostatectomy, subjects received 600 units/kg of rHuEPO 1 and 2 weeks prior to the procedure. 18 Outcomes revealed that more than 90% of participants in the treatment group did not require allogenic blood transfusion. Furthermore, men who did require allogenic transfusion typically needed only 1 to 2 units, a substantial decrease from the half dozen units normally required for the procedure.…”

“…However, a retrospective parallelgroup review of oncology and predialysis CKD (pCKD) inpatients examined the cost-effectiveness of darbepoetin alfa and rHuEPO. 18 The analysis compared an aggregate administered dose of the two ESAs. Recombinant human erythropoietin offered a cost reduction of nearly 50% when compared to darbepoetin ($755 vs $1127 oncology patients, P < .0001; $479 vs $723 pCKD patients, P < .0001).…”

“…The Centers for Medicare and Medicaid Services (CMS) publicized a review of reimbursement for most ESA use following the FDA safety alert. 18 While the reimbursement of ESAs for chemotherapy-induced anemia continues, CMS has issued a stop payment for ICD-9 code 285.22, the treatment of anemia due to cancer. Additionally, CMS will not reimburse the use of ESAs for the following: B-12 or folate-induced anemia, anemia due to erythroid cancers, prophylaxis against chemotherapy-induced anemia or decreased tumor hypoxia, cancer patients with uncontrolled hypertension, and patients with EPO resistance.…”

Running Head: Feasibility of Blood Management. Feasibility Study of a Blood Management Program in the Mike O'Callaghan Federal Hospital

“…Proponents often cite improved patient outcomes, reduced risk of infection, and cost savings as three legitimate benefits to implementing a blood management program (Society for the Advancement of Blood Management, 2008). Depending on the demographics of the patient population, anemia can be present in as many as 50% of surgical patients (Jaspan, 2007). A number of the processes and techniques discussed in the research address the potential benefits of blood management to anemic patients.…”